[A therapeutic approach towards chronic granulomatous disease].
Chronic granulomatous disease (CGD) is a primary immunodeficiency (PID) characterized by the inability of phagocytes to produce reactive oxygen intermediates (ROIs) due to a defect in the NADPH oxidase complex. Recent studies have revealed that ROIs are involved in inflammatory signaling in phagocytes, illuminating the underlying mechanisms of hyper-inflammation in CGD. CGD patients frequently suffer from CGD-associated bowel inflammation, granuloma, and life-threatening infections. Based on the discovery of the regulatory function of ROIs in the immune response, therapeutic methods for excessive inflammation focusing on inflammatory cytokines are being developed for CGD. Although hematopoietic stem cell (HSC) transplantation (HSCT) is a curative therapy for CGD, successful transplants greatly depend on HSC source selection and the degree of matching of potential donors. Gene therapy trials for PID have been performed on over 120 patients with no HLA identical donor for HSCT, and have demonstrated clinical benefits. Genotoxicity in HSC gene therapy trials has expanded our knowledge on the mechanisms of vector-associated clonal expansion of gene-modified cells, which will advance gene therapy development using self-inactivating retrovirus and lentivirus vectors. We will discuss the complications of HSCT for CGD. We will then outline the status of gene therapy approaches in the treatment of CGD.
Department of Human Genetics, National Center for Child Health and Development.
Toshinao
T
Kawai
D016207:Cytokines / Q000378:metabolism; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006105:Granulomatous Disease, Chronic / Q000209:etiology* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D058990:Molecular Targeted Therapy; D019255:NADPH Oxidases / Q000172:deficiency; D010586:Phagocytes / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D013792:Thalidomide / Q000627:therapeutic use
D016207:Cytokines; D018836:Inflammation Mediators; D017382:Reactive Oxygen Species; D013792:Thalidomide; D019255:NADPH Oxidases